NotableLead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLCShow 6 more changesShow less
Enrollment closed, study ongoing
Primary completion moved earlier from Aug 13, 2027 to Feb 17, 2027
Study completion moved earlier from Jan 11, 2030 to Jul 18, 2029
Eligibility criteria expanded, about 8 words
Secondary endpoints: details revised at 1 of 5 entries
Study sites revised (50)
MinorSite details revised at 2 of 50 sitesv13
MinorTrial sites expanded: 46 → 50 locationsv12
MinorStudy sites: 45 to 46v11
MinorStudy sites: 44 to 45v10
Show 2 earlier versionsHide 2 earlier versions
MinorStudy sites: 43 to 44v9
MinorStudy sites: 41 to 43v8
MinorTrial sites expanded: 38 → 41 locationsv7
MinorTrial sites expanded: 28 → 38 locationsv6
MinorTrial sites expanded: 6 → 28 locationsv5
MinorStudy sites: 4 to 6v4
NotablePrimary endpoint(s) modifiedv3Show 5 more changesShow less
Recruitment opened
Trial sites expanded: 0 → 4 locations
Start date changed from estimate of Apr 22, 2026 to Apr 20, 2026
Eligibility criteria expanded, about 32 words
Secondary endpoints: 4 to 5
MinorStudy description expanded, about 27 wordsv2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA.
In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.